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Background: Down Syndrome (DS) is caused by trisomy of chromosome 21, which includes the gene for the
amyloid precursor protein (APP) and leads to overproduction of beta-amyloid. Clinical-pathological studies indicate
that individuals with DS begin demonstrating Alzheimer’s disease (AD) pathology during adolescence and that
100% exhibit such changes by age 40. Individuals with DS therefore represent a highly enriched population for AD.
Additionally, owing to their baseline intellectual disability, people with DS represent a more vulnerable group of
individuals as compared with other populations. Given the recent developments in AD biomarkers, combined with
the prospect of achieving greater efficacy with earlier therapeutic intervention, it is logical to include adults with DS
in prevention trials for AD.
Discussion: The US Food and Drug Administration has released draft guidance on drug development for early-stage
AD, based on the understanding that AD is a progressive disease with symptoms developing decades after the disease
process has begun. New biomarkers now permit detection of AD pathology in asymptomatic individuals such that there
now exists an opportunity to conduct clinical trials of potentially disease-modifying drugs in the earliest stages of the
disease and perhaps have the greatest chance of demonstrating efficacy. As such, clinical trials are being actively planned
or conducted in individuals with causative mutations in the APP, presenilin-1 (PSEN1), and presenilin-2 (PSEN2) genes.
Summary: Individuals with DS comprise perhaps the largest group of people with genetically determined AD, with a
worldwide population of about 6 million people. Only by inclusion can we provide access to rational therapies that offer
the greatest chance of benefiting this highly at-risk population.Introduction
Preclinical Alzheimer’s disease
Converging evidence from longitudinal studies of clinic-
ally normal older and familial Alzheimer’s disease (AD)
cohorts strongly suggests that the AD pathophysiological
process begins decades before the manifestation of clinical
dementia. Recent advances in biomarkers, including amyl-
oid positron emission tomography (PET), Tau PET, and
volumetric magnetic resonance imaging (MRI), and cere-
brospinal fluid studies permit presymptomatic detection
of AD pathology. Hypothetical models have been pro-
posed in which these biomarkers become increasinglyCorrespondence: mrafii@ucsd.edu
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and symptoms emerge [1]. Longitudinal studies of familial
AD have provided substantial support for and refinement
of such models [2,3].
Mutations of all genes known to be involved in familial
AD - presenilin-1 (PSEN1), PSEN2, and amyloid precur-
sor protein (APP) - contribute to increased absolute or
relative production of the 42-amino-acid-length cleavage
product of APP, beta-amyloid (Aβ), which is the main con-
stituent of the amyloid plaques that characterize AD [4].
This tight link between genetic determinants of AD and
the overproduction of Aβ is compelling support for the
amyloid hypothesis and has been the focal point in the de-
velopment of disease-modifying drugs for AD.licensee has exclusive rights to distribute this article, in any medium, for 12
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prior to the onset of cognitive symptoms and before
extensive neurodegeneration has occurred. A decade
of negative anti-amyloid trials in mild to moderate
AD supports the notion that disease-modifying treatment
in the dementia stage may simply be too late. The field of
AD drug development has therefore steadily marched earl-
ier and earlier in the disease continuum, evaluating anti-
amyloid treatments in prodromal AD and, most recently,
in preclinical AD. Although autosomal dominant mutation
carriers represent less than 2% of all AD cases, such co-
horts are now being intensely studied in secondary preven-
tion trials of AD using anti-amyloid drugs, given the
opportunity they afford for presymptomatic intervention.
Discussion
Down syndrome is preclinical Alzheimer’s disease
Down syndrome (DS), or trisomy 21, affects 400,000
people in the US and has an incidence of 1 out of 691
live births [5]. It is caused by meiotic non-disjunction,
leading to an extra copy of chromosome 21, on which
the APP gene resides. Consequently, there is increased
APP mRNA and protein expression as well as higher
levels of Aβ [6]. Because of this overproduction of Aβ,
by the age of 40, virtually all people with DS show the
same neuropathological changes as is seen in AD [7].
Moreover, the cholinergic losses seen in the brains of in-
dividuals with DS are identical to those observed in AD
[8]. In contrast to sporadic AD, however, amyloid pla-
ques and neurofibrillary tangles in DS start developing
in people as early as 12 years of age [9].
Recent data also indicate that AD biomarker changes
in DS are similar to those observed in familial and spor-
adic AD. There is a sixfold increase in plasma Aβ in in-
dividuals with DS as compared with age-matched non-
DS individuals [10]. Results of amyloid PET imaging
from individuals with DS are also consistent with those
seen in non-DS individuals with AD [11]. And, as in famil-
ial and sporadic AD, the presence of the apolipoprotein E
ɛ4 allele is associated with greater accumulation of Aβ pro-
tein in the brains of adults with DS [12] and greater risk of
an earlier age of onset of dementia [13]. The link between
triplication of the APP gene and subsequent overproduc-
tion of Aβ leading to AD dementia in DS is further sup-
ported by the case of a DS individual with partial trisomy of
chromosome 21 who was disomic for the APP gene and
who did not develop dementia or any AD pathology [14].
Postmortem studies also indicate that adults with DS
have the same prominent pattern of cerebral atrophy in-
volving the medial temporal lobe structures as has been
reported in the early stages of familial and sporadic AD
[15]. Volumetric MRI studies of age-related brain changes
in DS demonstrate the same pattern of hippocampal-
specific atrophy observed in AD. Furthermore, thehippocampal atrophy in DS correlates with changes in
memory measures [16].
In DS, in which intellectual disability is lifelong, the
question arises as to how changes in cognition and func-
tioning can be reliably related to the emergence of AD
symptomatology. It should be noted that baseline intel-
lectual disability in DS is relatively static. Results from
recent biomarker studies suggest that these techniques
may be able to accurately discriminate progressive brain
changes due to AD age-related changes in DS. Moreover,
DS individuals who are over 40 years old show cognitive
decline in somewhat discrete phases. Initially, there is an
isolated, slowly progressive memory decline [17], analo-
gous to the mild cognitive impairment stage of AD in the
sporadic population, in which memory loss is the earliest
neuropsychological deficit. This phase is followed by a de-
cline in other cognitive functions and is coincident with
functional decline and dementia onset [17]. Thus, older
adults with DS represent a population in which the neuro-
psychological profile of cognitive change due to AD can
be followed in conjunction with biomarker changes de-
cades before dementia occurs.
Imperative for Alzheimer’s disease prevention in Down
syndrome
The number of older DS adults in the US is increasing.
In fact, from 1979 through 2003, the prevalence of DS
increased from 9.0 to 11.8 per 10,000 live births in 10
US regions [18]. This increase is due partially to the in-
crease in the number of women who conceive after age
35 [19]. In addition, people with DS have experienced
significant increases in life expectancy as a result of re-
duced institutionalization and improved access to medical
care, such as surgical intervention for congenital heart de-
fects [20]. With increased life expectancy, there has been
an increase in the prevalence of older DS adults with
dementia. It is currently estimated that there are over
200,000 people with DS over the age of 55 in the US [21].
Over 30% of DS adults more than 50 years old and over
50% of DS adults more than 60 years old have been diag-
nosed with AD dementia [22]. By the age of 70, approxi-
mately 75% of individuals with DS have dementia [23].
Alzheimer’s disease prevention trials in Down syndrome
Given the high risk of people with DS developing AD, it
is quite reasonable to consider prevention trials in this
population. We have sufficient knowledge about AD to
design and conduct secondary prevention studies in
other genetically determined populations. Undeniably,
there is more to learn about DS, but that does not pre-
clude inclusion of this group in AD prevention trials in
which the incidence and pathology of AD are well
understood. One can envision a relatively small, early-
stage study confirming feasibility and determining effect
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late-stage trial. Variance in the rate of cognitive decline
as well as signals on putative AD biomarkers in the initial
phase of development would be used to calculate the sam-
ple size required, as well as the duration of treatment, for
a definitive late-stage trial. Recent studies using amyloid
PET imaging demonstrate that deposition of fibrillar
amyloid is most dynamic between ages 35 and 55. This
age range may be an appropriate window to assess anti-
amyloid therapeutics.
Ultimately, however, endpoints in AD prevention trials
in DS will be cognitive outcomes as these will have the
greatest translatability to clinical meaningfulness. The
US Food and Drug Administration recently provided
guidance on drug development for the treatment of pre-
clinical AD [24]. This guidance indicates that an effect
on a valid and reliable cognitive assessment used as a
single primary efficacy measure would be considered for
approval in the context of a patient with positive bio-
markers of AD [25]. Instruments will need to be sensi-
tive for detecting change over time in relation to age,
baseline performance, and other participant characteris-
tics. Such valid cognitive assessment tools currently exist
for DS [26-28].
Summary
Multiple lines of evidence suggest that individuals with
DS suffer exactly the same pathological process in later
life as individuals with the other forms of AD. Indeed,
there is little to distinguish the pathological changes
in either condition. In DS, triplication of the APP gene
leads to the overproduction of Aβ and drives amyloido-
genic pathways leading to plaques, tangles, and neu-
rodegeneration. Owing to the 100% prevalence of AD
pathology in adults with DS, individuals with DS rep-
resent a well-defined subgroup of predetermined AD.
With 6 million people worldwide, DS is the largest popu-
lation of predictable AD cases. By including individuals
with DS in prevention trials, there is an opportunity to
provide access to potentially disease-altering therapies to
this highly at-risk population.
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